December 16, 2025 06:56 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Centre moves to replace MGNREGA with 'G Ram G', sets stage for winter session showdown | Messi surrounded by VIPs, fans rage: Five held in stadium vandalism case | 'Messi was uncomfortable, lost his cool!': Ex-India footballer reveals what really happened at chaotic Kolkata stadium | PM Modi embarks on historic three-nation visit to Jordan, Ethiopia, and Oman | Caught in Thailand! Fugitive Goa nightclub owners detained after deadly fire kills 25 | After Putin’s blockbuster Delhi visit, Modi set to host German Chancellor Friedrich Merz in January | Delhi High Court slams govt, orders swift compensation as IndiGo crisis triggers fare shock and nationwide chaos | Amazon drops a massive $35 billion India bet! AI push, 1 million jobs and big plans revealed at Smbhav Summit | IndiGo’s ‘All OK’ claim falls apart! Govt slaps 10% flight cut after weeklong chaos | Centre finally aligns IndiGo flights with airline's operating ability, cuts its winter schedule by 5%

Philippines healthcare providers administer vaccine approved for prevention of Dengue

| | Feb 23, 2016, at 05:00 am
Kolkata/Lyon, Feb 22 (IBNS): Sanofi Pasteur, the vaccines division of Sanofi, announced on Monday that vaccinations with Dengvaxia have commenced in the Philippines following official receipt of the first shipment of the vaccine earlier this month.
Dengvaxia, a tetravalent dengue vaccine, was approved in the Philippines on 22 December 2015 for the prevention of disease caused by all four Dengue types in individuals from 9-45 years of age living in endemic areas. 
 
The vaccine is administered in three doses given over a one-year period. Asia bears 70% of dengue fever burden globally with an estimated 67 million people being sickened by the disease annually. 
 
In the Philippines alone, over 110,000 people on average get Dengue every year. Asian endemic countries spend an estimated 6.5 billion USD annually in both direct medical and indirect costs due to Dengue.
 
“This is truly a great moment in the history of vaccinology,” states Guillaume Leroy, Vice-President of Dengue Vaccine, Sanofi Pasteur. “Dengvaxia’s availability for administration by healthcare providers in the Philippines, to be followed closely by the initiation of a public sector immunization program in the country is a landmark event for global Dengue prevention and a great achievement for the people of the Philippines.”
 
Medical Societies in the Philippines held a media event in Manila earlier this month to welcome receipt of the first shipment of Dengvaxia to the country.
 
In attendance, Dr. Rose Capeding, chief of the Research Institute for Tropical Medicine’s department of microbiology, noted that the Philippines participated in all three phases of the clinical development of the vaccine and that healthcare providers there were delighted to be able to begin vaccinating against dengue, which continues to pose a major public health threat to the nation.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.